Institute led by UW Nobel winner uses AI to build molecular scissors targeting disease proteins

Led by Nobel laureate David Baker, researchers at UW Medicine's Institute for Protein Design have used AI to engineer ...

New study reveals the shocking financial burden faced by ALS patients

A new study by ALS Canada is highlighting how much the disease is costing Canadians, including patients and their families.

"We Are Undeniable": ALS Association Launches Campaign to Confront Insurance Denials

The ALS Association today launched We Are Undeniable, a national campaign to help people living with ALS fight insurance ...

Wearable cyborg training linked to longer walking distances in people with ALS

Could a wearable robot help people with amyotrophic lateral sclerosis (ALS) walk farther? A new study from Toho University in ...

‘It’s really staggering’: ALS carries an estimated annual cost of $628.2M per year

Peter Boshyk and CEO of ALS Canada Tammy Moore on the financial impacts of the disease and the action that needs to be taken ...
The Manila Times

seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases

Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary SeRAS® technologyExpansion of the company’s laboratory and analytical capabilities with funding from ...
Rutland Herald

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS ...